UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/563,210	01/03/2006	Michael Sanders	18655-225894	1041	
	26694 7590 07/31/2008 VENABLE LLP			EXAMINER	
P.O. BOX 3438		PESELEV, ELLI			
WASHINGTO	N, DC 20043-9998		ART UNIT	PAPER NUMBER	
			1623		
			MAIL DATE	DELIVERY MODE	
			07/31/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/563,210	SANDERS, MICHAEL
Office Action Summary	Examiner	Art Unit
	Elli Peselev	1623
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period in Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) ☐ Responsive to communication(s) filed on 16 M 2a) ☐ This action is FINAL . 2b) ☐ This 3) ☐ Since this application is in condition for alloware closed in accordance with the practice under E	s action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 5-7,12-14,17 and 18 is/are pending in 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 5-7, 12-14, 17 and 18 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	wn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	cepted or b) objected to by the liderawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)	4) 🗔 Intoniano Comercia	(PTO 412)
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	4)	ate

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 5-7, 12-14, 17 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sanders (WO 02/32233 A2).

Sanders discloses the use of aivlosin for the treatment of microbial infections in swine and poultry (page 1) but does not disclose the treatment of specific infections encompassed by the present claims. However, since aivlosin is a well known antibiotic known to be useful in the treatment of microbial infections in pigs and poultry, it would have been prima-facie obvious to a person having ordinary skill in the art at the time the claimed invention was made to also use aivlosin for the treatment of specific microbial infections encompassed by the present claims.

Applicant's arguments filed May 16, 2008 have been fully considered but they are not persuasive.

Applicant contends that Sanders does not disclose specific microbial infections encompassed by the present claims. Applicant further contends that the fact that an antibiotic such as Pulmotil is less effective in treating specific bacterial infections encompassed by the present claims, demonstrates the unpredictability of the efficacy of antibiotic agents. These arguments have not been found persuasive. Note that while Pulmotil antibiotic is less effective against the claimed microbial infections, it still has some effect. Thus, it would have been prima facie obvious to a person having ordinary

Art Unit: 1623

skill in the art at the time the claimed invention was made would to try aivlosin in the treatment of the claimed microbial infections, because such a person would have expected such treatment to result in at least some efficacy.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 8.00-4.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Jiang can be reached on (571) 272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/563,210 Page 4

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Elli Peselev

/Elli Peselev/

Primary Examiner, Art Unit 1623